TAG letter urging the Advisory Committee on Immunization Practices (ACIP) to maintain the recommendation of a universal hepatitis B virus (HBV) birth dose vaccine in the United States.
On Sept. 3 20+ organizations — including TAG — signed this Infectious Diseases Society of America’s (IDSA) joint statement calling for the resignation of Sec. Robert F. Kennedy Jr. The letter outlines the many ways Kennedy’s “agenda” is meant to undermine science and public health.
Save the Date: Monday, October 20, 2025 , when our Research in Action Awards return this fall! We'll honor some of the most brilliant activists, scientists, and leaders in the fight to end HIV, tuberculosis (TB), and hepatitis C (HCV). Get your tickets now!
The current administration’s Executive Order on Ending Crime and Disorder on America’s streets is yet another direct attack on science and basic human rights.
This Hepatitis C virus (HCV) storyboard describes the experience of Sibusiso Dlamini in Tsawne, South Africa. Sibusiso is a young man who began using substances for leisure in high school, and later in life switched to injecting substances for a stronger high.
TAG is organizing this webinar on July 29 for community organizations and advocates to raise awareness about the HCV Elimination bill, and prepare them to meet and engage with their Senators during the August recess in their district offices or Town Hall meetings.
TAG's Senior TB Project Associate, Erin McConnell, created this 'zine about TAG for Pride 2025. It's about fighting back, and goes over current threats, action items, and action steps on how to show up.
This publication discusses findings from two surveys conducted among end users and healthcare providers/policy makers to understand their perspectives on, and the facilitators and barriers to potential long-acting therapies for Hepatitis C virus (HCV) cure currently being developed by the LONGEVITY consortium, funded by the global health agency Unitaid.
This webinar will provide a platform to learn about the findings from the Longevity HCV and TB end users and healthcare providers/policy makers surveys, and for community members, especially marginalized populations across the world, to engage with the researchers developing these Long-Acting Therapies.